Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia. by Tandler, C. et al.
cancers
Article
Neutralization of B-Cell Activating Factor (BAFF) by
Belimumab Reinforces Small Molecule Inhibitor
Treatment in Chronic Lymphocytic Leukemia
Claudia Tandler 1,†, Moritz Schmidt 1,†, Jonas S. Heitmann 1, Julia Hierold 1, Jonas Schmidt 1,
Pascal Schneider 2, Daniela Dörfel 1, Juliane Walz 1,3 and Helmut R. Salih 1,3,*
1 Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German
Cancer Research Center (DKFZ), Department of Internal Medicine, University Hospital Tuebingen,
72076 Tuebingen, Germany; Claudia.Tandler@med.uni-tuebingen.de (C.T.);
Moritz.Schmidt@med.uni-tuebingen.de (M.S.); Jonas.Heitmann@med.uni-tuebingen.de (J.S.H.);
Wild.Julia85@googlemail.com (J.H.); Jonas.Schmidt@med.uni-tuebingen.de (J.S.);
Daniela.Doerfel@krh.de (D.D.); Juliane.Walz@med.uni-tuebingen.de (J.W.)
2 Department of Biochemistry, University of Lausanne, 1066 Epalinges, Switzerland; Pascal.Schneider@unil.ch
3 DFG Cluster of Excellence 2180 ‘Image-Guided and Functional Instructed Tumor Therapy’ (iFIT),
Eberhard Karls University, 72076 Tuebingen, Germany
* Correspondence: Helmut.Salih@med.uni-tuebingen.de; Tel.: +49-7071/29-83275
† These authors contributed equally to this work.
Received: 29 August 2020; Accepted: 21 September 2020; Published: 23 September 2020


Simple Summary: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in
Western countries. Despite the substantial progress achieved by the recent introduction of the novel
small molecule inhibitors idelalisib, ibrutinib and venetoclax in CLL treatment, therapy resistance
occurs frequently and the disease so far remains incurable. In the present study we report that BAFF,
a member of the TNF protein family, protects CLL cells from treatment-induced cell death. In turn,
the therapeutic effects of idelalisib, ibrutinib and venetoclax can be reinforced by neutralizing BAFF
with belimumab, an antibody which presently is clinically approved for treatment of systemic lupus
erythematosus. Based on the data presented in this study, a clinical study to evaluate whether drug
repurposing of belimumab for BAFF neutralization can serve to improve response to small molecule
inhibitor treatment in CLL is in preparation.
Abstract: The introduction of idelalisib, ibrutinib and venetoclax for treatment of chronic lymphocytic
leukemia (CLL) has greatly improved long term survival of patients. However, many patients do
not achieve complete remission and suffer from development of resistance upon treatment with
these small molecule inhibitors. Here we report that the TNF family member B-cell activating factor
(BAFF) mediates resistance of CLL cells to idelalisib, ibrutinib and venetoclax by sustaining survival
and preventing apoptosis of the malignant B cells as revealed by analysis of cellular ATP levels and
mitochondrial membrane integrity as well as caspase activation, respectively. As BAFF also plays a
prominent role in autoimmune diseases, the BAFF-neutralizing antibody belimumab was developed
and approved for treatment of systemic lupus erythematosus (SLE). When we employed belimumab
in the context of CLL treatment with idelalisib, ibrutinib and venetoclax, BAFF neutralization was
found to significantly increase the sensitivity of the leukemic cells to all three small molecule inhibitors.
Notably, BAFF neutralization proved to be beneficial independently of clinical stage according to
Binet and Rai or IgVH mutational status. Our results identify drug repurposing of belimumab for
neutralization of BAFF to complement small molecule inhibitor treatment as a promising therapeutic
approach in CLL that is presently undergoing clinical evaluation.
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1. Introduction
Chronic lymphocytic leukemia (CLL) is the most common form of adult leukemia in Western
countries [1]. In the last decades, patients suffering from CLL were treated with conventional
chemotherapy in the vast majority of cases. After the introduction of the monoclonal CD20
antibody rituximab, which largely improved overall survival when added to chemotherapy,
chemo-immunotherapy became the standard of care [2,3]. The increasing understanding of disease
pathophysiology in CLL recently enabled the development of small molecule inhibitors specifically
targeting molecular structures of central importance for prolonged survival of B cells. Three such
compounds, the B cell receptor inhibitors ibrutinib and idelalisib as well as the Bcl-2 antagonist
venetoclax have meanwhile been approved for CLL treatment and all profoundly improved long
term survival of patients [4–6]. Nonetheless, many patients do not achieve complete remission upon
treatment with these small molecule inhibitors, even in combination with CD20 antibodies, and disease
progression was observed in 7% of idelalisib/rituximab-treated patients after six months, in 10% of
ibrutinib/rituximab-treated patients after three years, and in 15% of venetoclax/ rituximab-treated
patients after two years [5,7,8]. Disease progression after initial response is mainly caused by occurrence
of resistance over the course of therapy [9–12].
A variety of different cytokines, chemokines and other factors are meanwhile recognized to protect
CLL cells from spontaneous and drug-induced apoptosis. Available data have identified the tumor
necrosis factor (TNF) family member B-cell activating factor (BAFF) to play a major role for survival of
both healthy and malignant B cells [13–16]. BAFF binds to three different receptors: the ‘BAFF receptor’
(BAFFR), ‘transmembrane activator and cyclophilin ligand interactor’ (TACI), and ‘B-cell maturation
antigen’ (BCMA). Pro-survival signals mediated by BAFF in B cells are mainly transduced via BAFFR,
resulting in downstream activation of the NF-κB signaling pathway [16–18]. Several preclinical studies
have meanwhile demonstrated that BAFF mediates pro-survival effects also in the context of B cell
malignancies under therapy with currently approved treatment regimens [19–24].
From a clinical perspective, BAFF is mainly known for its role in autoimmune diseases: elevated
BAFF serum levels have been detected in patients suffering from rheumatoid arthritis and SLE
representing clinical pathologies that at least in part are caused by aberrant B cell activation [25,26].
In line, high serum levels of BAFF proved to be unfavorable prognostic factors due to their correlation
with disease activity [27,28]. Based on its involvement in disease pathophysiology, BAFF neutralization
using a monoclonal antibody termed belimumab has been established and was approved for the
treatment of patients with SLE. We reported recently that BAFF protects primary CLL cells from
rituximab-induced natural killer (NK) cell killing, and sensitivity of CLL cells to NK cell cytotoxicity
could be restored by belimumab [24]. Here we demonstrate that BAFF impairs the therapeutic efficacy of
the small molecule inhibitors idelalisib, ibrutinib and venetoclax and provide evidence that belimumab
can resensitize CLL cells to treatment. The results of our study further serve as rationale for a
multicentric phase II clinical study in which we will evaluate BAFF neutralization in combination with
small molecule inhibitor application for treatment of CLL.
2. Results
2.1. BAFF Dose-Dependently Protects Primary CLL Cells from Treatment-Induced Cell Death
In a first step, we determined suitable concentrations of the small molecule inhibitors idelalisib,
ibrutinib and venetoclax for our in vitro studies based on plasma peak levels achieved in leukemia
patients [29–31]. Then we incubated primary CLL cells with the selected concentration of idelalisib,
ibrutinib or venetoclax in combination with increasing amounts of BAFF. Analyses of ATP levels
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using CellTiterGlo® (CTG; Promega, Madison, WI, USA) assays revealed that BAFF dose-dependently
protected CLL cells from drug-induced cell death (Figure 1A and data not shown). Notably, protective
effects were already observed at concentrations as low as 1 ng/mL with more pronounced effects
observed at higher levels. Of note, results of reports on BAFF levels (patho-)physiologically occurring
in CLL differ substantially ranging from a median of 0.08 ng/mL [32] to 920 ng/mL [14]. Therefore and
to allow for optimal elucidation of the effects of the small molecule inhibitors, 500 ng/mL BAFF was
chosen as concentration for subsequent experiments.
Since CD20 antibodies are frequently included in current treatment regimens employing the
small molecule inhibitors, we excluded that rituximab did influence the effect of BAFF on treatment
susceptibility of the CLL cells (Figure 1B). Based on our results, we thus omitted addition of CD20
antibodies in subsequent experiments.
Notably, BAFF increased relative CLL cell viability in vitro also in the absence of small molecule
inhibitors, which is in accordance with findings reported by Novak et al. [33] (Figure 1C). It remains
unclear so far whether this finding is due to prevention of cell death caused by the in vitro culture
conditions or caused by promotion of CLL cell survival as suggested by findings of Enzler et al. [34]
obtained in animal models.
Next we analyzed the influence of BAFF on treatment-induced apoptosis of the CLL cells in
greater detail. To this end, we employed analysis of the mitochondrial membrane potential as detected
by TMRE using flow cytometry. With all three small molecule inhibitors, we observed an induction
of apoptosis as revealed by a decrease of the cell population with intact mitochondrial membrane
potential, even though the extent varied between idelalisib, ibrutinib and venetoclax (Figure 1D).
With all three compounds, presence of BAFF prevented the treatment-induced loss of mitochondrial
membrane potential (Figure 1D).
To confirm these findings by analysis of a more downstream apoptotic event, we next analyzed
how BAFF affected treatment-induced activation of caspase-3, a central executioner caspase which
is basically responsible for cell degradation in the process of programmed cell death. To this end,
primary CLL cells were exposed to idelalisib, ibrutinib or venetoclax in the presence or absence of
BAFF followed by flow cytometry. The three small molecule inhibitors were found to induce caspase-3
activation to different extents, and in line with our previous results, BAFF reduced the processing of
procaspase-3 into its active form in all cases (Figure 1E,F).
Cancers 2020, 12, x 3 of 15 
 
using CellTiterGlo® (CTG; Promega, Madison, WI, USA) assays revealed that BAFF 
dose-dependently protected CLL cells from drug-induced cell death (Figure 1A and data not 
shown). Notably, protective effects were already observed at concentrations as low as 1 ng/mL with 
more pronounced effects observed at higher levels. Of note, results of reports on BAFF levels 
(patho-)physiologically occurring in CLL differ substantially ranging from a median of 0.08 ng/mL 
[32] to 920 ng/mL [14]. Therefore and to allow for optimal elucidation of the effects of the small 
molecule inhibitors, 500 ng/mL BAFF was chosen as concentration for subsequent experiments. 
Since CD20 antibodies are frequently included in current treatment regimens employing the 
small molecule inhibitors, we excluded that rituximab did influence the effect of BAFF on treatment 
susceptibility of the CLL cells (Figure 1B). Based on our results, we thus omitted addition of CD20 
antibodies in subsequent experiments. 
Notably, BAFF increased relative CLL cell viability in vitro also in the absence of small molecule 
inhibitors, which is in accordance with findings reported by Novak et al. [33] (Figure 1C). It remains 
unclear so far whether this finding is due to prevention of cell death caused by the in vitro culture 
conditions or caused by promotion of CLL cell survival as suggested by findings of Enzler et al. [34] 
obtained in animal models.  
Next we analyzed the influence of BAFF on treatment-induced apoptosis of the CLL cells in 
greater detail. To this end, we employed analysis of the mitochondrial membrane potential as 
detected by TMRE using flow cytometry. With all three small molecule inhibitors, we observed an 
induction of apoptosis as revealed by a decrease of the cell population with intact mitochondrial 
membrane potential, even though the extent varied between idelalisib, ibrutinib and venetoclax 
(Figure 1D). With all three compounds, presence of BAFF prevented the treatment-induced loss of 
mitochondrial membrane potential (Figure 1D). 
To confirm these findings by analysis of a more downstream apoptotic event, we next analyzed 
how BAFF affected treatment-induced activation of caspase-3, a central executioner caspase which is 
basically responsible for cell degradation in the process of programmed cell death. To this end, 
primary CLL cells were exposed to idelalisib, ibrutinib or venetoclax in the presence or absence of 
BAFF followed by flow cytometry. The three small molecule inhibitors were found to induce 
caspase-3 activation to different extents, and in line with our previous results, BAFF reduced the 
processing of procaspase-3 into its active form in all cases (Figures 1E,F). 
 
Figure 1. Cont.
Cancers 2020, 12, 2725 4 of 15
Cancers 2020, 12, x 4 of 15 
 
 
Figure 1. Protection of CLL cells from small molecule inhibitor-induced cell death by BAFF. (A,B) 
Peripheral blood mononuclear cells (PBMC) of CLL patients (n = as indicated) were exposed to 
idelalisib (500 nM), ibrutinib (500 nM) or venetoclax (2 nM) in combination with increasing 
concentrations of recombinant human BAFF (rhBAFF) in the absence (A) or presence (B) of rituximab 
(10 µg/mL). Cell viability was determined by measurement of ATP levels using the CTG assay. 
Results were normalized to the respective untreated samples, and relative viability was calculated. 
Boxes indicate the median and interquartile range, and whiskers represent data up to 1.5 × the 
interquartile range. RM one-way ANOVA with Tukey’s multiple comparisons tests were used for 
statistical analysis. (C) PBMC of CLL patients were exposed to rhBAFF in the presence or absence of 
idelalisib (n = 11), ibrutinib (n = 12) or venetoclax (n = 9) and then analyzed using CTG assays. Results 
were normalized to respective untreated samples without BAFF exposure (dotted line), and relative 
viability was calculated. For idelalisib and ibrutinib, a two-tailed t-test and for venetoclax a Wilcoxon 
matched-pairs signed rank test was used. (D) Mitochondrial membrane potential of primary CLL 
cells in the presence or absence of rhBAFF (500 ng/mL) was determined by staining with TMRE 
(Sigma, St. Louis, MO, USA) in 7-AAD-CD3- CD5+CD19+ cells using flow cytometry. Combined 
results of the percentages of TMRE+ primary CLL cells treated with idelalisib (10 µM, n = 7), ibrutinib 
(10 µM, n = 7) or venetoclax (5 nM, n = 10) are shown. For idelalisib and ibrutinib, a two-tailed t-test 
and for venetoclax a Wilcoxon matched-pairs signed rank test was used. (E,F) Active caspase-3 in 
Fixable Aqua-CD3-CD5+CD19+ cells in the presence or absence of rhBAFF (500 ng/mL) was 
determined intracellularly using flow cytometry. In (E), an example for the gating strategy is shown; 
(F) depicts combined results of the percentages of active caspase-3+ primary CLL cells treated with 
idelalisib (50 µM, n = 7), ibrutinib (10 µM, n = 8) or venetoclax (7.25 nM, n = 6). A two-tailed t-test was 
used for statistical analysis. Statistically significant differences (p < 0.05) are indicated by *. 
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or the protective effect of BAFF varied amongst patients depending on clinical features or molecular 
characteristics as reflected by the Binet as well as the Rai staging system and the IgVH mutational 
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Figure 1. Protection of CLL cells fro small molecule inhibitor-induced cell death by B FF.
(A,B) Peripheral blood mononuclear cells (PBMC) of CLL patients (n = as indicated) were exposed to
idelalisib (500 nM), ibrutinib (500 nM) or venetoclax (2 nM) in combination with increasing concentrations
of recombinant human BAFF (rhBAFF) in the absence (A) or presence (B) of rituximab (10 µg/ L).
Cell viability was determined by measurement of ATP levels using the CTG assay. Results were
normalized to the respective untreated samples, and relative viability was calculated. Boxes indicate
the median and interquartile range, and whiskers represent data up to 1.5 × the interquartile range.
RM one-way ANOVA with Tukey’s multiple comparisons tests were used for statistical analysis.
(C) PBMC of CLL patients were exposed to rhBAFF in the presence or absence of idelalisib (n = 11),
ibrutinib (n = 12) or venetoclax (n = 9) and then analyzed using CTG assays. Results were normalized to
respective untreated samples without BAFF exposure (dotted line), and relative viability was calculated.
For idelalisib and ibrutinib, a two-tailed t-test and for venetoclax a Wilcoxon matched-pairs signed
rank test was used. (D) Mitochondrial membrane potential of primary CLL cells in the presence or
absence of rhBAFF (500 ng/mL) was determined by staining with TMRE (Sigma, St. Louis, MO, USA) in
7-AAD-CD3- CD5+CD19+ cells using flow cytometry. Combined results of the percentages of TMRE+
primary CLL cells treated with idelalisib (10 µM, n = 7), ibrutinib (10 µM, n = 7) or venetoclax (5
nM, n = 10) are shown. For idelalisib and ibrutinib, a two-tailed t-test and for venetoclax a Wilcoxon
matched-pairs signed rank test was used. (E,F) Active caspase-3 in Fixable Aqua-CD3-CD5+CD19+
cells in the presence or absence of rhBAFF (500 ng/mL) was determined intracellularly using flow
cytometry. In (E), an example for the gating strategy is shown; (F) depicts combined results of the
percentages of active caspase-3+ primary CLL cells treated with idelalisib (50 µM, n = 7), ibrutinib
(10 µM, n = 8) or venetoclax (7.25 nM, n = 6). A two-tailed t-test was used for statistical analysis.
Statistically significant differences (p < 0.05) are indicated by *.
2.2. BAFF Mediates Anti-Apoptotic Effects in CLL Cells Irrespective of Clinical Stage or IgVH
Mutational Status
Next, we studied whether the susceptibility to treatment with idelalisib, ibrutinib or venetoclax,
or the protective effect of BAFF varied amongst patients d pending on clinical features or mole ular
characteristics as reflected by the Bin t as well a the Rai staging system and the IgVH mutational status,
respe tively [35–37]. Accordingly, th extent of cell death induced by the small molecule inhibitors
and the protective effect of B FF was determin d using respective patient samples.
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No relevant differences were observed when we employed the two clinical staging systems,
neither with regard to the therapeutic effect nor the protective potential mediated by BAFF (Figure 2A,B).
Likewise, no influence of the IgVH mutational status was observed (Figure 2C), which is consistent with
previous reports from Herman et al. regarding the therapeutic effect of idelalisib and ibrutinib [38,39].
Overall this indicates that BAFF confers resistance to small molecule inhibitor treatment over the entire
spectrum of disease.Cancers 2020, 12, x 5 of 15 
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Figure 2. Clinical Binet stage, Rai stage and IgVH mutational status do not impact response to s all
molecule inhibitor treatment or survival-promoting effects of BAFF. PBMC from different CLL patients
were exposed to idelalisib (500 nM), ibrutinib (500 nM) or venetoclax (2 nM) in the presence or absence
of rhBAFF (500 ng/mL) and cell viability was determined by CTG assays. Results were normalized
to the respective untreated samples n relative viability was calculated. The difference between
the untreated sample n the small molecule inhibitor-treated sample (left side) and the differenc
between the respective small molecule inhibit r-treated sample alone and in combination with rhBAFF
(right side) were analyzed. R sults are epicted according to the cli ical Binet stage (A), R i stage
(B) and IgVH mutational status (C). For statistical analyses, ordinary one-way ANOVA ith Tukey’s
multiple comparisons tests were performed in (A, left) for idela isib (A vs. B p = 0.9766, A vs. C
p = 0.8850, B vs. C p = 0.7557) and ibrutinib (A vs. B p = 0.7739, A vs. C p = 0.5810, B vs. C p = 0.9138),
and a Kruskal-Wallis test with Dunn’s multiple comparisons test f r venetoclax (A vs. B p = 0.8564,
A vs. C p = 0.9279, B vs. C p > 0.9999) (idelalisib: Binet A n = 4, Binet B n = 5, Binet C n = 5; ibrutinib:
Binet A n = 5, Binet B n = 7, Binet C n = 5; venetoclax: Binet A n = 4, Binet B n = 6, Binet C n = 5).
In (A, right), a Kruskal-Wallis with Dunn’s multiple comparisons test was used for idelalisib (A vs. B
p > 0.9999, A vs. C p > 0.9999, B vs. C p > 0.9999), and ordinary one-way ANOVA with Tukey’s multiple
comparisons test for ibrutinib (A vs. B p = 0.4560, A vs. C p = 0.3997, B vs. C p = 0.9753) and venetoclax
A vs. B p = 0.5154, A vs. C p = 0.9090, B vs. C p = 0.7447). In (B, left), unpaired two-tailed t-tests were
used for idelalisib (0-II vs. III-IV p = 0.4797) and ibrutinib (0-II vs. III-IV p = 0.4288), and for venetoclax
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(a two-tailed Mann-Whitney test (0-II vs. III-IV p = 0.4396) (idelalisib: Rai 0-II n = 9, Rai III-IV n = 5;
ibrutinib Rai 0-II n = 11, Rai III-IV n = 6; venetoclax Rai 0-II n = 10, Rai III-IV n = 5). In (B, right),
a two-tailed Mann-Whitney test was used for idelalisib (0-II vs. III-IV p = 0.7972) and venetoclax
(0-II vs. III-IV p = 0.0992), and an unpaired two-tailed t-test was performed for ibrutinib (0-II vs. III-IV
p = 0.6485). In (C), unpaired two-tailed t-tests were used for idelalisib (left: unmutated vs. mutated
p = 0.8180, right: unmutated vs. mutated p = 0.7128), ibrutinib (left: unmutated vs. mutated p = 0.6248,
right: unmutated vs. mutated p = 0.8103) and venetoclax (left: unmutated vs. mutated p = 0.2135,
right: unmutated vs. mutated p = 0.1358) (idelalisib: IgVHunmut n = 5, IgVHmut n = 4; ibrutinib:
IgVHunmut n = 5, IgVHmut n = 4; venetoclax: IgVHunmut n = 4, IgVHmut n = 4). No statistically
significant differences were observed, as indicated by “not significant (ns)”.
2.3. Belimumab Abrogates Survival-Promoting Effects of BAFF
Next we exposed primary CLL cells to idelalisib, ibrutinib or venetoclax in the presence or absence
of BAFF with or without belimumab or control antibody and determined CLL cell viability by CTG
assays. In line with the results described above, treatment of primary CLL cells with the three small
molecule inhibitors caused a relevant decrease of cell viability, and the CLL cells were rescued by
BAFF. When these analyses were conducted in the presence of belimumab, we found that BAFF
neutralization re-sensitized CLL cells to treatment with all small molecule inhibitors (Figure 3A).
The effect of belimumab again held true over the entire spectrum of disease, as correlation of our
in vitro results with clinical stage (Figure 3B,C) or IgVH mutational status (Figure 3D) did not reveal
any statistically significant differences.
2.4. Belimumab Neutralizes Anti-Apoptotic Properties of BAFF
Finally, we aimed to determine whether and how BAFF neutralization by belimumab specifically
affected apoptosis induction by the small molecule inhibitors. To this end, leukemic cells derived from
different CLL patients were incubated with BAFF in the presence or absence of belimumab or control
antibody and exposed to idelalisib, ibrutinib and venetoclax. Flow cytometric measurements revealed
a statistically significant reduction of mitochondria membrane disruption in the presence of BAFF,
and belimumab restored the susceptibility to mitochondria-dependent apoptosis with all compounds
(Figure 4A,C).
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B n = 6, Binet C n = 5). In (C), unpaired two-tailed t-tests were performed for idelalisib (Rai 0-II n = 9,
Rai III-IV n = 5) and ibrutinib (Rai 0-II n = 11, Rai III-IV n = 6), and two-tailed Mann-Whitney tests for
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Figure 4. Neutralization of BAFF by belimumab re-sensitizes primary CLL cells to apoptosis induction
by small molecule inhibit r treatment. Apoptosis in CLL cells was determined either by measurements
of itochondrial membrane potential with TMRE (A,C) or staining of active caspase-3 (B,D) using
flow cytometry. (A,C) PBMC of CLL patients were incubated with idelalisib (10 µM, n = 6), ibrutinib
(10 µM, n = 7) or venetoclax (5 nM, n = 9) in the presence or absence of rhBAFF (500 ng/mL),
belimumab or co trol anti ody (10 µg/mL each) followed by staining with CD3, CD5, CD19, 7-AAD
and TMRE. Representative results in (A) are depicted for venetoclax showing the p rcentage of TMRE+
(= non-apop otic) CLL cells, and combined results are shown in (C) for each small molecule inhibitor.
For statistical analyses, a RM one-way ANOVA with Holm-Sidak’s multiple comparisons test was
performed for idelalisib and ibrutinib, and Wilcoxon matched-pairs signed rank tests for venetoclax.
(B,D) Activation of caspase-3 was analyzed i primary CLL cells exp sed to idel lisib (50 µM, n = 6),
ibrutinib (10 µM, n = 8) or venet clax (7.25 nM, n = 7) in the presence or absence of rhBAFF (500 ng/mL),
belimumab or control antibody (10 µg/mL each). Cells were stained with CD3, CD5, CD19, Fixable
Aqu , an anti-active caspase-3 antibody and represent tive res lts are depicted in (B) as histograms,
including the percentage of active caspase-3+ (= apoptotic) CLL cells and the isotype control signal
(open histograms). Combined results are shown in (D). A paired t-test was performed for idelalisib,
a Wilcoxon matched-pairs signed rank test for ibrutinib, and a RM one-way ANOVA with Tukey’s
multiple comparisons tests for venetoclax. Statistically significant differences (p < 0.05) are indicated
by *.
These results were confirmed by analyses of caspase-3 activation, which further revealed that
belimumab prevents the anti-apoptotic effect of BAFF on CLL cells exposed to the small molecule
inhibitors (Figure 4B,D). Together, these results demonstrate that the BAFF-neutralizing antibody
belimumab might serve as an efficient tool for restoring susceptibility of CLL cells to all so far approved
small molecule inhibitors.
3. Discussion
With exception of the few patients qualifying for allogeneic stem cell transplantation, CLL so far
remains an incurable disease. This holds true despite the recent progress achieved by introduction of
targeted treatment with the meanwhile approved small molecule inhibitors idelalisib, ibrutinib and
venetoclax. All three compounds achieve superior outcomes with regard to overall and progression-free
survival when compared to chemo-immunotherapy, the former standard of care in CLL [7,8,40].
However, alike observed for many other anti-cancer drugs, the potency of these small molecule
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inhibitors frequently declines in the course of treatment due to emerging resistance of the malignant
cells. Beyond mutations that alter the structure of the target proteins and result in a lowered affinity to
the inhibitors, a plethora of cell-mediated and soluble anti-apoptotic and pro-survival factors directly
and indirectly contribute to treatment resistance [9–11,41–44].
Several studies have meanwhile provided evidence for the critical role of the TNF family
member BAFF in CLL pathophysiology and therapy resistance [19,22–24,33]. BAFF mediates its
effects via a variety of mechanisms, among which the NF-κB pathway represents the main route for
pro-survival signal transduction resulting, among others, in upregulation of anti-apoptotic proteins
like Bcl-2 and Mcl-1 [16,18,45]. The resulting imbalance between pro- and anti-apoptotic factors
contributes to a longer lifetime of the malignant B cells and reportedly impairs susceptibility to
chemotherapeutics [16,18,19,33,45–47].
We report here that BAFF impairs the efficacy of idelalisib, ibrutinib and venetoclax in CLL cells as
revealed by analysis of treatment-induced cell death including mitochondria- and caspase-dependent
apoptosis. Our findings are in line with findings of McWilliams et al. [22] and Sanchez-Lopez et al. [23],
who reported similar effects in analyses involving ibrutinib and venetoclax, respectively. In contrast,
Herman and coworkers [38,39] did not observe an effect of BAFF on the efficacy of idelalisib and
ibrutinib. The reasons for the discrepancy of the findings of Herman et al. compared to our results
and those of the other investigators remain so far unclear; certainly, differing experimental conditions,
e.g., the employed BAFF concentrations, have contributed to the same. Notably, as already stated
above conflicting findings have been reported with regard to the prevalence of BAFF in human serum.
Menteşe et al. [32] described median soluble BAFF levels of 0.08 ng/mL in CLL patients, whereas
median concentrations of 376 ng/mL (ranging from 93 to 8914 ng/mL) and 920 ng/mL (±54 ng/mL)
were described by Molica et al. [48] and Haiat et al. [14], respectively. Of note, in all studies, levels
in CLL patients were found to be lower than those of healthy controls [14,32,48]. This has been
interpreted as evidence that BAFF may have been “depleted” from serum due to binding to its receptors
expressed on CLL cells [49]. In addition, higher BAFF levels may prevail locally, e.g., in lymph nodes
or proliferation centers.
Further evidence for a protective effect of BAFF in CLL is provided by two studies in mice:
Enzler et al. employed Eµ-TCL1xBAFF-Tg CLL mice presenting with high expression levels of BAFF
and used BAFFR-Fc and BCMA-Fc fusion proteins to demonstrate that BAFF neutralization reduces
leukemic burden in these animals [34,50]. In line, McWilliams et al. reported prolonged survival of
SCID mice adoptively transferred with splenocytes from leukemic Eµ-TCL1 mice when an antibody
that blocks murine BAFFR was applied to increase the therapeutic efficacy of ibrutinib [22].
As belimumab is not cross-reactive with mice [51], we employed primary human CLL cells ex
vivo in our analyses which revealed that neutralization of human BAFF sensitizes patient CLL cells to
treatment with idelalisib, ibrutinib and venetoclax. Of note, this beneficial effect was independent
of the patients’ clinical stage according to Binet and Rai or IgVH mutational status. Although our
in vitro experiments do not provide direct evidence to what extent endogenous BAFF provides survival
signals to CLL cells, in particular when considering that, as discussed above, the extent of “bioactive”
BAFF in CLL patients is yet unclear, these results demonstrate that BAFF confers resistance of CLL
cells to all three small molecule inhibitors. Considering that B cells in humans reportedly require
BAFF for survival it is reasonable to assume that blockade of BAFF in patients would sensitize CLL
cells to treatment-induced cell death [52,53]. This in turn opens up a path for direct translation into
clinical application: as belimumab is already approved for treatment of SLE, extensive data on the
pharmacokinetics and safety profile in humans are readily available and allow for rapid repurposing
of the antibody for CLL treatment [52,54]. This is even more since a phase I clinical study with CLL
patients evaluating atacicept, which binds BAFF and its homologue APRIL has already provided
evidence for the clinical safety of BAFF neutralization [55]. The finding that atacicept lacked therapeutic
efficacy applied as monotherapy in this trial further supports our rationale to combine belimumab
with application of small molecule inhibitors to increase the sensitivity of CLL cells to treatment.
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In a recent study we reported that BAFF also mediates resistance of CLL cells to treatment
with rituximab and other CD20 antibodies [24]. These antibodies are integral components of CLL
treatment that mediate their therapeutic efficacy in large part by inducing antibody-dependent
cellular cytotoxicity of NK cells [56]. Our former study not only provided a functional explanation
for the reportedly impaired efficacy of rituximab to induce NK cell reactivity in CLL, but also
introduced BAFF neutralization as means to increase the efficacy of CD20 antibody treatment in this
disease [24,57]. As combined application of idelalisib, ibrutinib or venetoclax with anti-CD20 antibodies
has meanwhile been approved and rapidly changed treatment paradigms in CLL [58,59], we reason
that belimumab may reinforce CLL treatment by a dual mechanism that comprises sensitization to both,
(i) antibody-dependent cellular cytotoxicity induced by CD20 antibody treatment and (ii) induction of
cell death by small molecule inhibitors.
Among the three small molecule inhibitors, venetoclax appears particularly suitable for first
clinical evaluation in a combinatorial approach with BAFF neutralization, because the combination of
this Bcl-2 inhibitor and rituximab is the recommended second line treatment (category 1 according to
NCCN Guidelines v.4.2020) employing targeted therapy together with CD20 antibody application.
Addition of belimumab appears warranted as available data revealed a clonal evolution of CLL cells
upon venetoclax treatment, despite its high efficacy [11,43,58,60]. This highlights the need for effective
combinatorial approaches allowing for early elimination of minimal residual disease, prevention of
development of secondary resistance and/or relapse and reduction of treatment time/toxicity.
Based on the rationale outlined in this paper we have conceptualized a randomized clinical
phase II study in which the safety and efficacy of combining subcutaneous application of belimumab
with rituximab/venetoclax as second line treatment of relapsed/refractory CLL will be evaluated.
The documents are presently submitted to the regulatory authorities, recruitment is expected to start
within this year. This clinical trial will ultimately elucidate the physiological relevance of our results
and whether BAFF neutralization can serve to further improve treatment options of patients.
4. Materials and Methods
4.1. Primary Material
Peripheral blood mononuclear cells (PBMC) were obtained from 36 CLL patients that had not
undergone anti-cancer treatment for at least three months (mean CD5+/CD19+ fraction of 90.0% (range
81.1–96.0%), mean age 67.3 years (range 41–92), male (27), female (9); for additional characteristics
see Table S1) at the University Hospital Tuebingen, Germany in the time from 2014–2019 after written
informed consent and in accordance with the Helsinki protocol. The study was performed according
to the guidelines of the local ethics committee (13/2007V). Mutational status of the variable region
of the immunoglobulin heavy chain (IgVH) was assessed at time of initial diagnosis. Classification
of the CLL patients according to the Binet or Rai staging system was based on clinical features and
biomarkers at time of blood donation. For in vitro experiments, only PBMC samples with a CLL cell
content of at least 80% were used.
4.2. Reagents
Recombinant human BAFF (rhBAFF) was from PeproTech (Rocky Hill, NJ, USA). Rituximab,
trastuzumab and bevacizumab were from Roche (Basel, Switzerland), and belimumab was from
GlaxoSmithKline (Brentford, UK). In neutralization experiments, binding of belimumab to rhBAFF
was allowed for 45–60 min at room temperature prior to adding. Idelalisib and ibrutinib were
from Selleckchem (Munich, Germany), and venetoclax was from Active Biochem LTD (Kowloon,
Hong Kong). The antibodies CD5-APC, CD5-PE, CD19-FITC and anti-active caspase-3-AlexaFluor647
were purchased from BD Pharmingen (San Diego, CA, USA), CD3-eFluor450 was from eBioscience
(San Diego, CA, USA). Rabbit isotype control-AlexaFluor647 was from Cell Signaling Technology
(Danvers, MA, USA), LIVE/DEAD™ Fixable Aqua Dead Cell Stain Kit for 405 nm was from Invitrogen
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(Waltham, MA, USA), 7-aminoactinomycin D (7-AAD) and CD3-APCFireTM 750 were from BioLegend
(San Diego, CA, USA). Tetramethylrhodamine ethyl ester perchlorate (TMRE) was purchased from
Sigma (St. Louis, MO, USA) and used at a concentration of 50 nM. Primary cells were cultivated
in RPMI-1640 GlutaMAXTM (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with
10% fetal calf serum (Biochrom AG, Berlin, Germany) and 1% penicillin/streptomycin (Lonza, Basel,
Switzerland).
4.3. Cell Viability Assay
PBMC from CLL patients were plated in a 96-well plate (NunclonTM Delta Surface, Thermo
Fisher Scientific, Waltham, MA USA) at a density of 5 × 104 per well and incubated with the indicated
therapeutics in the presence or absence of rhBAFF, belimumab or control antibody (trastuzumab,
bevacizumab). After 72 h, cell viability was measured using the CellTiterGlo® Luminescent Cell
Viability Assay (CTG) from Promega (Madison, WI, USA) according to the manufacturers’ instructions.
4.4. Analysis of the Mitochondrial Membrane Potential and Caspase-3 Activation
PBMC of different CLL patients were seeded at a density of 2 × 106 per well in a 24-well plate
(Corning Inc., Kennebunk, ME, USA) and pre-incubated with rhBAFF in the presence or absence
of either control antibody or belimumab for 24 h. Then small molecule inhibitors were added in
combination with rhBAFF, control antibody or belimumab as indicated before.
Mitochondrial membrane potential was determined in CLL cells after 16 h (venetoclax), 48 h
(ibrutinib) or 72 h (idelalisib) of incubation. After addition of CD3, CD5, CD19 antibodies and TMRE
in combination with 7-AAD according to manufacturers’ instructions, patient samples with at least
30% TMRE+ cells were included in the analysis.
For determination of caspase-3 activity in CLL cells after either 16 h (venetoclax) or 24 h of treatment
with idelalisib or ibrutinib, PBMC were stained with CD3, CD5, CD19 and Fixable Aqua. Subsequent
intracellular staining was performed using the Cytofix/Cytoperm buffer and Perm/wash solution
(BD Biosciences, San Jose, CA, USA) with an anti-active caspase-3 or rabbit isotype control antibody
according to manufacturers’ instructions. Patient samples with 10% or less basal caspase-3 activity
as determined by analysis on either a FACSCanto II or a LSRFortessa cytometer (BD Pharmingen,
San Diego, CA, USA) are shown.
4.5. Statistical Analysis
In general experiments were performed three times with various primary samples,
and representative experiments as well as combined data are shown. For CTG assays, technical
triplicates were performed enabling the calculation of average values and standard deviations.
Statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, San Diego, CA,
USA). Normality distribution was tested using the Shapiro-Wilk normality test. For normally distributed
data, p-values were calculated either by two-tailed t-tests, or repeated measures (RM) or ordinary
one-way ANOVA and subsequent Tukey’s or Holm-Sidak’s multiple comparison tests. In case of
non-normal distribution, p-values were calculated either by a Wilcoxon matched-pairs signed rank test,
a two-tailed Mann-Whitney test or a Kruskal-Wallis test followed by Dunn’s correction for multiple
comparisons. Where indicated, statistically significant (p < 0.05) differences between two groups are
marked by “*”. Boxes depict the 25th to 75th percentiles, whiskers extend to the minimum and up to
the maximum value, centre values represent mean, error bars represent standard deviation (s.d.) if not
declared otherwise.
5. Conclusions
Here, we report that drug repurposing of the clinically available BAFF-neutralizing antibody
belimumab, which is approved for treatment of SLE, re-sensitized primary CLL cells to the small
molecule inhibitors idelalisib, ibrutinib and venetoclax. Based on our findings, we conclude that the
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combined application of belimumab with rituximab/venetoclax for treatment of relapsed/refractory
CLL constitutes a promising therapeutic approach to elucidate whether neutralization of BAFF can
serve to further improve treatment options of patients.
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